Behavioral therapy involves building healthier actions through learned skills. Explore different evidence-based techniques.
More individuals with multiple food allergies receiving dupilumab vs. placebo after omalizumab tolerated 1,043 mg peanut protein after stopping treatment, but this was not significant, according to a ...
LUND, Sweden, Feb. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has ...
Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...
Black and Hispanic patients with severe allergies are less likely to get a common treatment, allergen immunotherapy, compared to white patients, according to Penn State College of Medicine researchers ...
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of ...
A new mRNA vaccine stopped allergens from causing dangerous immune reactions and life-threatening inflammation in mice, according to researchers from the Perelman School of Medicine at the University ...
Imlifidase is an antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies and inhibits IgG-mediated immune response.8 It ...
PARIS--(BUSINESS WIRE)--Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results